Olle Ringdén Research Group
Allogeneic Hematopoietic Stem Cell Transplantation: Research Profile
- With genomic and immunological techniques predict patients at risk of severe graft-versus-host disease (GVHD).
- Optimally use the antileukemic effect by GVHD.
- Improve immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) by the development of cytotoxic T-cells (CTL) against Epstein-Barr virus, cytomegalovirus, adenovirus and aspergillus.
- Expand T-cells from cord blood transplants to be used for immunotherapy.
- Develop the graft-versus-cancer effect in solid tumors, such as prostate cancer, pancreas carcinoma, colon carcinoma, renal carcinoma and liver carcinoma. Develop CTL against prostate as immunotherapy in prostate cancer.
- Culture and expand stromal cells from different tissues like placenta and study alloreactivity in vitro. Study mechanisms. Use stromal cells for treatment and prevention of GVHD in prospective studies.
The Olle Ringdén Research Group and Laboratories are located within the Karolinska University Hospital Huddinge, Division of Clinical Immunology F71-79 and CAST B87.
N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell mediated immunity in vitro.
European Journal of Immunology 41:1143-1153, 2011.
Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.
Transplantation 90:1022-1029, 2010.
Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoietic stem-cell transplantation.
Transplantation 87: 467-472, 2009.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
Blood 113:3110-3118, 2009.
Mesenchymal stem cells exert differential effects on alloantigen- and virus-specific T-cell responses.
Blood 112: 532-541, 2008.